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Abstract
Background—Other than Kaposi's sarcoma (KS)-associated herpesvirus and CD4+ T cell 
lymphopenia, the mechanisms responsible for KS in the context of HIV are poorly understood. 
One recently explored pathway of HIV pathogenesis involves induction of the enzyme 
indoleamine 2,3 dioxygenase-1 (IDO), which catabolizes tryptophan into kynurenine and several 
other immunologically active metabolites that suppress T cell proliferation. We investigated the 
role of IDO in the development of KS in HIV disease.
Methods—In a case-control study among untreated HIV-infected Ugandans, cases were adults 
with KS and controls were without KS. IDO activity was assessed by the ratio of plasma 
kynurenine to tryptophan levels (KT ratio), measured by liquid chromatography tandem mass 
spectrometry.
Results—We studied 631 HIV-infected subjects: 222 KS cases and 409 controls. Non-KS 
controls had a higher median plasma KT ratio (130, IQR: 90 to190 nM/μM) than cases (110, IQR: 
90 to 150 nM/μM) (p = 0.004). After adjustment for age, sex, CD4 count and plasma HIV RNA 
level, subjects with the highest (fourth quartile) plasma KT ratios had a 59% reduction (95% CI: 
27% to 77%) in the odds of KS compared to those with the lowest (first quartile) levels. KS was 
also independently associated with lower CD4+ count, higher plasma HIV RNA, and men.
Conclusions—Among HIV-infected individuals, greater activity of the kynurenine pathway of 
tryptophan catabolism, as evidenced by higher levels of plasma KT ratio, was associated with 
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lower occurrence of KS. Some consequences of immune activation in HIV infection might 
actually suppress certain cancers.
Keywords
tryptophan; kynurenine; indoleamine 2,3-dioxygenase-1; HIV; Kaposi's sarcoma; plasma HIV 
RNA; Africa
Kaposi's sarcoma (KS) was a harbinger of the HIV epidemic [1] and, despite the marked 
reduction in its incidence since the advent of effective antiretroviral therapy (ART) [2, 3], 
remains the most common malignancy in people with HIV worldwide [4]. In sub-Saharan 
Africa, the extent of the HIV epidemic has resulted in KS becoming one of the most 
frequently reported cancers among all adults [4]. Although the discovery of the causative 
viral agent for KS, Kaposi's sarcoma-associated herpesvirus (KSHV, also known as human 
herpesvirus 8), was a landmark accomplishment in the etiology of KS [5], this virus is not 
sufficient to cause KS. In fact, other than KSHV [5] and CD4+ T cell lymphopenia [3, 6], 
the specific biological mechanisms responsible for the development of KS, particularly in 
sub-Saharan Africa, are poorly understood.
A potential mechanism for KS that has recently received attention in HIV pathogenesis is 
the kynurenine pathway of tryptophan catabolism [7-10]. The induction of indoleamine 2,3-
dioxygenase-1 (IDO) in activated monocytes and dendritic cells by interferon-γ and other 
inflammatory mediators in HIV-infected individuals causes catabolism of tryptophan into 
kynurenine and several other downstream catabolites with immunologic properties [11, 12]. 
Depletion of tryptophan [13] and the accumulation of the catabolites kynurenine and 
picolinic acid [14] directly inhibit T cell proliferation, potentially contributing to immune 
deficiency. In addition to its role in HIV infection, the induction of the kynurenine pathway 
has been implicated in maternal tolerance of the fetal allograft [15] and in the evasion of 
host immune responses by several cancers [16]. In KS etiology, we hypothesized that the 
kynurenine pathway might promote KS by decreasing immune surveillance. Alternatively, 
given the inflammatory histopathological nature of KS lesions, it is conceivable that the 
induction of the kynurenine pathway may inhibit emergence of KS by suppression of 
lymphocyte proliferation.
To begin to address the role of the kynurenine pathway in the development of KS, we 
studied it directly in HIV-infected adults newly diagnosed with KS in sub-Saharan Africa. 
IDO activity can be quantified by measuring the ratio of plasma kynurenine to tryptophan 
(KT ratio), where a high KT ratio reflects heightened IDO induction. We also took this 
opportunity to formally investigate, in Africa, the relationship between KS and other factors 
that have been studied in other populations, such as CD4+ T cell count, plasma HIV RNA, 
sex and age. The overarching objective was to identify causal determinants of KS in order to 
inform both the development of interventions to prevent KS and target groups for earlier 
ART initiation.
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Methods
Overall Design
We conducted a case-control study of untreated HIV-infected adults (≥ 18 years old) in 
Uganda to investigate the relationship between plasma KT ratio and KS independent of 
known confounders.
Study Population
Cases were individuals with KS sampled between April 2007 and February 2011 throughout 
Uganda, who were enrolled in the Antiretrovirals for Kaposi's Sarcoma (ARKS) study based 
at the Infectious Diseases Institute, Kampala, Uganda [17]. To be eligible for ARKS, 
subjects had to have histologically-confirmed KS, with the exception of a few patients with 
highly characteristic oral lesions that could not be easily biopsied. No subjects had what was 
considered advanced KS by virtue of having an urgent indication for chemotherapy. 
Specifically, no individuals had any functionally disabling complication of KS. Subjects also 
could not have evidence of current active untreated opportunistic infection (e.g., tuberculosis 
or cryptococcosis) or other malignancy. While ARKS was a randomized trial of different 
ART regimens for treatment of KS, the patients in the current case-control study were 
studied at baseline prior to initiating ART. All ARKS enrollees with available plasma 
specimens were included as cases in the present analysis.
Controls were individuals without KS enrolled in the Uganda AIDS Rural Treatment 
Outcomes (UARTO) Cohort. UARTO is a consecutive sample of ambulatory HIV-infected 
adults residing within 60 kilometers of and starting ART at the Immune Suppression 
Syndrome (ISS) Clinic at Mbarara Regional Referral Hospital in southwestern Uganda. 
ART at this clinic is prescribed on the basis of CD4+ T cell count or clinical conditions, 
according to Ugandan national antiretroviral treatment guidelines [18]. For the present 
study, we included all UARTO participants without KS who were consecutively enrolled 
between June 2005 and April 2010 and who had available plasma specimens, and we studied 
them prior to ART initiation. The absence of KS in the controls was based on patient self-
report as well as review of medical records at the ISS Clinic. The ISS Clinic has an active 
skin punch biopsy service for histological confirmation of KS sponsored by the International 
Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium.
Amongst both cases and controls, we excluded any woman with a history of pregnancy in 
the prior 12 months given the influence of pregnancy on the kynurenine pathway [19] and 
the fact that pregnant women were excluded from the ARKS trial.
Measurements
Questionnaire-based—The ARKS and UARTO studies used the same instruments for 
all measurements of socio-demographic characteristics, medical history, and clinical 
assessment. Within these instruments, we used the Medical Outcomes Study to determine 
physical health status and mental health status [20] and the Filmer-Pritchett asset index, as 
previously described [21], to characterize socioeconomic status.
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Laboratory—All biological tests for the cases and controls were performed in the same 
laboratories on samples obtained prior to the start of ART. Tryptophan and kynurenine 
levels were measured on cryopreserved plasma samples by liquid chromatography tandem 
mass spectrometry as previously described [22]. Plasma HIV RNA level was measured 
using the Amplicor HIV Monitor version 1.5 or the Cobas Taqman HIV-1 version 1.0 assays 
(Roche, Branchburg, NJ). CD4+ T cell counts were assessed using the FACSCalibur system 
(Becton Dickinson, San Jose, CA). Two enzyme immunoassays [23, 24] and one direct 
immunofluorescence assay [25, 26] were used to detect antibodies to KSHV, and the results 
of these three assays were interpreted according to a previously described algorithm [27].
Statistical Analysis
Multivariable logistic regression was used to examine the relationship between plasma KT 
ratio and KS. In our base-case analysis, we were guided by our pre-specified perception of 
the biological system and hence adjusted for CD4+ T cell count, plasma HIV RNA, age and 
sex [3, 6, 28, 29]. Because of ample sample size and number of cases, we did not attempt to 
reduce the number of covariates. In additional analyses, we also adjusted for other proxies of 
HIV disease progression not captured by the aforementioned variables, including body mass 
index, hemoglobin, mental health status, physical health status and socioeconomic status 
[30-32]. In sensitivity analyses, we first restricted KS cases to those recruited from areas 
with moderate to high malaria endemicity, and then we also separately restricted the non-KS 
controls to those without suspicion of TB within the first 6 months after initiation of ART. 
Finally, we also performed an analysis in which we restricted the non-KS control group to 
subjects who were KSHV-antibody-positive.
We assessed for non-linearity in continuous predictor variables using splines, and variables 
were transformed or categorized where necessary. Influential observations were checked 
using post-estimation plots of dfbetas, followed by sensitivity analyses on data points with 
high dfbetas. We also assessed for possible interactions with the primary predictor variable, 
KT ratio, and used a p value of 0.05 to guide reporting of interaction. The Hosmer-
Lemeshow test was used to examine goodness of fit. We used multiple imputation with 
iterative chained equations for missing values [33]. All analyses were performed using 
STATA 13 (College Station, TX, USA).
Results
Characteristics of the Study Population
A total of 631 untreated HIV-infected Ugandans were examined: 222 KS cases and 409 non-
KS controls. Men comprised 56% of the cases and 33% of the controls (Table 1). Compared 
to the controls, cases had a slightly higher median body mass index (21.4 versus 21.1kg/m2), 
lower hemoglobin (11.6 versus 12.2 g/dl), and higher plasma HIV RNA levels (5.3 versus 
5.1 copies/ml). Sixty nine percent and 75% of cases and controls, respectively, had a CD4+ 
T cell count ≤200 cells/μl; 13% and 3% of cases and controls respectively, had CD4+ T cell 
count >350 cells/μl. The cases had a wide spectrum of mucocutaneous KS ranging from oral 
lesions only to widespread cutaneous dissemination.
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Relationship between Plasma KT Ratio and KS
The median plasma KT ratio amongst all subjects was 120 (IQR: 90 to 180) nM/μM, which 
is higher than in HIV-uninfected individuals, at least in resource-rich settings [34]. The 
distribution of plasma KT ratio was more markedly skewed to the right in the controls 
compared to the cases (Figure 1). In an unadjusted analysis, the non-KS controls had a 
higher median plasma KT ratio (130, interquartile range [IQR]: 90 to190 nM/μM) than cases 
(110, IQR: 90 to 150 nM/μM) (p = 0.004). Specifically, there was a non-linear “threshold” 
relationship between plasma KT ratio and KS (Table 2). Compared to those with KT ratio in 
the lowest quartile (i.e., lowest values, KT ratio <90 nM/μM), there was no association with 
KS with increasing values of KT ratios until the highest values were reached. Those with 
KT ratio in the highest quartile (i.e., highest values, KT ratio >179 nM/μM) had a 50% 
reduction in the odds of KS. We observed similar results in a multivariable logistic 
regression model adjusting for age, sex, CD4+ T cell count and plasma HIV RNA level 
(Table 2). Compared to individuals with KT ratio in the lowest quartile, there was 59% 
reduction (95% CI: 27% to 77%; p = 0.002) in the odds of KS for those with KT ratio in the 
highest quartile. In an additional analysis, to attempt further adjust for the confounding 
effect of HIV disease progression, we also adjusted for body mass index, hemoglobin, 
mental health status, physical health status and asset index. In this analysis, we observed an 
even a stronger and more linear association between plasma KT ratio and KS. The 
association between KT ratio and KS was not modified by CD4+ T cell count, plasma HIV 
RNA level, sex or age (p value for interaction = 0.61, 0.84, 0.54, and 0.19 respectively).
Effects of Malaria and Tuberculosis on the Relationship between KT Ratio and KS
Given that Plasmodium species may induce IDO activity [35], and that all the non-KS 
controls were enrolled from areas with moderate to high malaria endemicity while 31% of 
the cases were enrolled from areas of low malaria endemicity [36], we examined whether 
the association between KT ratio and KS might be because of differences in malaria co-
morbidity between the cases and controls. In analyses restricted to the 153 KS cases 
recruited from areas with moderate to high malaria endemicity [36], we again observed, 
after adjustment for age, sex, CD4+ T cell count and plasma HIV RNA viral load, that 
individuals with KT ratio in the highest quartile had a reduction in the odds of KS compared 
to those in the lowest quartile (OR = 0.39; 95% CI: 0.20 to 0.77; Table 3). When we also 
adjusted for BMI, hemoglobin, mental health status, physical health status and asset index, a 
dose-response relationship was again observed. Imbalance in concurrent tuberculosis was 
also a concern because Uganda has a high prevalence of tuberculosis amongst patients 
initiating ART [37], Mycobacterium tuberculosis may induce IDO [38], and the ARKS 
study excluded persons with untreated tuberculosis while UARTO did not. To address this, 
we restricted our analyses to the non-KS controls without TB by excluding all subjects who 
were receiving any anti-tuberculosis medications at enrollment, or who were subsequently 
treated for tuberculosis within the first 6 months after ART initiation (n=62). Our findings of 
an independent inverse association between plasma KT ratio and KS remained consistent 
(Table 3).
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Effect of KSHV Infection on the Relationship between KT Ratio and KS
Consistent with prior data from this region, 40% of the 409 subjects in the non-KS control 
group were KSHV-antibody-positive. In an additional analysis in which we restricted the 
non-KS control group to only participants who were KSHV-antibody-positive and, again, 
adjusted for age, sex, plasma HIV RNA level, and CD4 count, we observed a somewhat 
stronger negative association between KT ratio and KS than in our analysis including all 409 
non-KS controls. Compared to individuals with KT ratio in the lowest quartile, there was 
71% reduction (95% CI: 42% to 86%; p=0.002) in the odds of KS for those with KT ratio in 
the highest quartile.
Other Determinants of KS
We observed that KS was also independently associated with male sex, higher BMI, lower 
hemoglobin, lower mental health status score, lower CD4+ T cell count, and higher plasma 
HIV RNA level (Table 2). The correlation with plasma HIV RNA was most notable with a 
dose-response relationship seen throughout most of the range of exposure and over a 5-fold 
greater odds of KS observed amongst those with RNA > 100,000 copies/ml compared to 
those with < 10,000 copies/ml.
Discussion
Other than KSHV infection and CD4+ T cell lymphopenia, the specific biological 
mechanisms responsible for the development of AIDS associated KS remain poorly 
understood. In this case-control study of untreated HIV-infected Ugandans, we have 
described a potentially new mechanism affecting the occurrence of KS. Specifically, greater 
activity of the kynurenine pathway of tryptophan catabolism was associated with a lower 
occurrence of KS. These data provide the first evidence suggesting a role of the kynurenine 
pathway of tryptophan catabolism in KS pathogenesis and may explain why some KSHV-
infected individuals with advanced AIDS fail to develop KS. We have also added to the 
knowledge base for how HIV infection causes KS by finding a strong independent 
association between plasma HIV RNA level and KS.
Our findings add to the growing literature regarding the kynurenine pathway of tryptophan 
catabolism in carcinogenesis [16]. In the majority of work to date, increased kynurenine 
pathway activity has been positively associated with the occurrence of cancer, which is 
generally attributed to the escape of tumor from immune surveillance [16]. IDO is expressed 
in both tumor cells and antigen-presenting cells in tumor-draining lymph nodes, and by 
fostering immune suppression, IDO activity facilitates the survival and growth of tumor 
cells expressing unique antigens that would normally be recognized as foreign [39, 40]. 
Indeed, increased serum KT ratio has been shown to correlate with disease progression and 
poor prognosis in certain cancers [41, 42]. In contrast, in our study, higher plasma KT ratio 
(reflecting higher levels of IDO activity) appeared protective against KS. Our results suggest 
that intact lymphocyte proliferation is necessary for the development of KS. The in vitro 
observation that malignant B lymphocyte cell growth is suppressed by IDO activity also 
supports this hypothesis [43]. A protective effect of the highest levels of IDO activity 
against KS is also compatible with the observation that KS often occurs at local sites of 
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inflammation [44] and the inflammatory nature histologically of KS lesions (i.e., an immune 
cell infiltrate). In addition, several inflammatory cytokines are increased in KS lesions and 
are capable of increasing lytic replication of KSHV [45]. Th1 cytokines from activated 
infiltrating T and B cells may also trigger KS lesion formation by promoting spindle cell 
proliferation and angiogenesis [45, 46]. That an inflammatory microenvironment fosters KS 
lesions suggests that IDO-derived local immune suppression could impair the development 
of KS. Alternatively, high levels of KSHV infection might suppress interferon-gamma-
induced IDO and lower KT levels as previously observed in other viral infections [47]. 
Experiments on KS tissue, and appropriate controls, to directly examine KT levels would be 
a natural next step to evaluate the biological plausibility of our finding.
We observed a stronger inverse association between plasma KT ratio and KS — in fact, a 
dose-response effect — when we also adjusted for other markers of HIV disease 
progression, namely BMI, mental health score, physical health score, asset index, and 
hemoglobin. Further interrogation of the regression models revealed that this change in the 
shape of the KT-KS relationship was caused solely by adjustment for hemoglobin (data not 
shown). We cannot, however, determine whether this further adjustment is warranted and 
hence whether the stronger association is valid. Specifically, because this is a cross-sectional 
study, we cannot distinguish between whether low hemoglobin is a common outcome of 
both KT ratio and KS (also known as a “collider” in epidemiologic parlance), or whether it 
is a proxy for a confounder (causally responsible for both KT ratio and KS), or a mediator 
(intermediary along the pathway) for the relationship between KT ratio and KS, and hence 
we presented the results of both adjusted models 1 and 2. While the latter two scenarios 
warrant adjustment for hemoglobin when trying to understand the direct causal effect of KT 
ratio on KS, the first scenario does not. In any case, whether or not hemoglobin is adjusted 
for, we consistently observed that having the highest level plasma KT ratio was associated 
with lower occurrence of KS.
As is often true in case-control studies, the principal limitation of our work concerns the 
selection of the controls. Because of the relative rarity of KS and the lack of a population-
based surveillance system in Uganda for the identification of KS as it occurs in the 
community, we were unable to assemble unassailable case and control groups sampled from 
a primary study base [48]. Instead, we took advantage of a large group of recently diagnosed 
cases of KS, compared them to a representative sample of persons without KS who were 
similarly advanced in their HIV infection by virtue of an indication for ART, and 
accommodated for any differences between the groups by statistical adjustment. 
Importantly, our case and control groups were not independently constructed and compared 
in retrospect with a piecemeal assemblage of measurements. Rather, the ARKS and UARTO 
studies were prospectively performed in parallel with identical questionnaire-based and 
laboratory measurements in anticipation of comparative research like the present study. 
While it remains possible that the UARTO-based control group was systematically enriched 
for patients with higher values of KT ratio, we feel our various analyses render this unlikely. 
First, the most obvious difference between the groups, their geographic residence, was 
addressed by restricting analysis in the case group to those living in malarious areas. In this 
sensitivity analysis, our primary inference was unchanged. Second, the potential for the 
control group to harbor patients with a greater prevalence of co-infections which are 
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stimulating IDO induction was addressed in our main analysis by extensive adjustment for 
determinants of co-infections (e.g., CD4+ T cell count) as well as manifestations of co-
infections (e.g., BMI). Furthermore, when we limited the control group to those without 
tuberculosis, we again saw no change in our inference. Although we were unable to directly 
examine the effect of potential differences in prevalence of soil transmitted helminthes, the 
species that may induce IDO [49, 50] are more prevalent in the geographic areas from which 
the cases were recruited [51]. Therefore, we would expect a bias towards the null. 
Nonetheless, as with any observational study, our findings require replication.
Consistent with prior research from resource-rich settings [29, 52], we found in untreated 
HIV-infected Africans that higher plasma HIV RNA levels were strongly associated with 
KS even after adjustment for CD4+ T cell count and other factors. The independent role of 
plasma HIV RNA provides clinical augmentation of earlier laboratory research suggesting a 
causative role of HIV per se in KS etiology [53]. CD4+ T cell lymphopenia was also 
independently associated with KS, as has been previously well established. Of note, that a 
CD4+ T cell count > 350 cells/μl appeared to carry a greater risk of KS than a CD4+ T cell 
count < 50/μl is likely an artifact of the patient sample and not a biologic phenomenon. That 
is, the non-KS controls were HIV-infected patients about to initiate ART according to local 
ART guidelines, which, for much of the period of the study, required a CD4+ T cell count < 
200 cells/μl or a World Health Organization stage IV condition [18]. Therefore, the majority 
of the controls had a CD4+ T cell count < 200 cells/μl. On the other hand, there was no 
restriction on the CD4+ T cell count for the KS cases, and, as seen elsewhere [3, 54], a 
relevant proportion of KS cases had a CD4+ T cell count > 350 cells/μl. This therefore 
explains why the KS cases are enriched, in comparison with the controls, for high CD4+ T 
cell counts. This difference in CD4+ T cell count distribution between cases and controls, 
however, does not explain the association between KT ratio and KS because CD4+ T cell 
count was statistically controlled for when assessing the KT ratio and KS relationship, and, 
furthermore, there was no statistical interaction between KT ratio and CD4+ T cell count. 
We also observed that lower hemoglobin was associated with KS which we speculate 
reflects anemia of chronic inflammation driven by elevated levels of inflammatory cytokines 
[55, 56] and/or KS involvement of the gastrointestinal tract with occult hemorrhage [57]. 
Similarly, we believe that the association between BMI and KS is also an example of 
reverse causality, explained by KS-induced lymphedema and associated weight gain. Like 
prior studies in this setting, we observed that male sex was independently associated with 
KS [28].
We note that the explosion of human subjects-based biological discovery in HIV/AIDS 
(sometimes called “translational” research) has not occurred in the study of KS [58]. The 
absence of translational research in KS is particularly regrettable in Africa where KS is 
among the most common cancers in the entire general population. The differences between 
Africa and settings like the U.S. in terms of human host, causative viral pathogen, and 
environment suggest that African KS science cannot simply survive by extrapolating from 
the translational work done in resource-rich settings. Now that biological measurement tools 
and research infrastructure such as ARKS, UARTO, and the AIDS Malignancy Consortium 
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are in place in sub-Saharan Africa, we hope that studies like ours will spur further African-
based translational work in KS etiopathogenesis.
In summary, we have demonstrated that higher IDO activity, as evidenced by higher plasma 
KT ratio, is associated with lower occurrence of KS amongst HIV-infected adults in Africa. 
The inverse relationship between KT ratio and KS is consistent with the inflammatory 
nature of KS lesions and suggests that intact lymphocyte proliferation is required for KS 
lesion development. Results from this study imply that some consequences of immune 
activation in HIV might actually suppress or mask certain cancers.
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Figure 1. 
Distribution of plasma KT ratio in KS cases and non-KS controls
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Table 1
Characteristics of the cases and controls
Characteristic KS Cases (n=222) Non-KS Controls (n=409)
Age, years 34 (28 to 40)* 35 (29 to 40)
Male sex 56% 33%
Physical health status† 53.3 (36.4 to 58.2) 54.0 (45.0 to 58.6)
Mental health status† 48.6 (37.7 to 56.7) 52.6 (45.9 to 58.7)
Asset index‡ 0.18 (−1.80 to 1.78) −0.58 (−1.82 to 0.86)
Body mass index, kg/m2 21.4 (19.4 to 23.1) 21.1 (19.4 to 23.4)
Hemoglobin, g/dl 11.6 (10.3 to 13.2) 12.2 (10.6 to 13.7)
HIV RNA, log10 plasma copies/ml 5.3 (5.0 to 5.6) 5.1 (4.6 to 5.6)
CD4+ T cells, count/μl
    < 50 35% 16%
    51-100 11% 18%
    101-200 23% 41%
    201-350 18% 21%
    > 350 13% 3%
Plasma KT Ratio, nM/uM, by quartile
    quartile 1 (34-89) 27% 24%
    quartile 2 (90-120) 28% 23%
    quartile 3 (121-179) 29% 23%
    quartile 4 (180-1369) 16% 30%
*
Median (interquartile range) unless indicated
†
Mental and Physical Health Status scores were derived using the Medical Outcomes Study-HIV survey. Responses to questions on 5 scales 
regarding vitality, cognitive function, quality of life, health distress and mental health are summarized in the Mental Health Status score, and 
responses to questions on 6 scales regarding general health, vitality, pain, physical, role and social function are summarized in the Physical Health 
Status score. Responses to individual questions are aggregated, and scores are converted to a 0-100 point scale, with 100 representing the best 
mental or physical health status.20
‡
The Filmer Pritchet index is a measure of socioeconomic status based on self-reported asset ownership and housing characteristics. Appropriate 
weights for individual questions are determined using the statistical method of principal components, and responses are aggregated to create the 
asset index score, which may be positive or negative with a median of zero. A higher score represents a higher socioeconomic status.21
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